

**JUBILANT PHARMA LIMITED**  
(Company Registration No. 200506887H)  
(Incorporated in the Republic of Singapore)  
Registered office: 80 Robinson Road, #02-00, Singapore 068898

November 11, 2021

**Singapore Exchange Securities Trading Limited**  
11 North Buona Vista Drive #06-07  
The Metropolis Tower 2  
Singapore 138589

Dear Sirs,

**Subject: Announcement**

Further to our disclosure dated May 31, 2021, we enclose a communication pertaining to the Groundbreaking Ceremony hosted by Jubilant HollisterStier LLC, USA, a wholly-owned subsidiary of the Company for expansion of its manufacturing facility.

This is for your kind information and records.

Thanking you,

Yours faithfully,  
For Jubilant Pharma Limited

Sd/-  
Shyam S. Bhartia  
Chairman and Managing Director

Encl.: As above



## **Jubilant Pharma Ltd.**

6 Temasek Boulevard, #20-06  
Suntec City Tower Four, Singapore 038986  
Tel.: +65 6235 4129  
[www.jubilantpharma.com](http://www.jubilantpharma.com)

## **Jubilant HollisterStier to Host Groundbreaking Ceremony for \$92 Million Expansion**

***Noida (UP), India, Thursday, November 11, 2021***

Spokane, WA – November 11, 2021: Jubilant HollisterStier LLC, a pharmaceutical contract manufacturer that is part of Jubilant Pharma Limited, announced plans to host a groundbreaking ceremony on Wednesday, November 17, 2021 at 11:00 am PT at their Spokane, Washington facility. The 50,000 square foot expansion will house a high-speed filling line and lyophilizers, which will increase the facility's sterile injectable capacity by 50%.

"Based on our trajectory analysis of the sterile injectable market, as well as ongoing conversations with existing partners, there is need to add capacity at our existing facility," said Amit Arora, President, Jubilant HollisterStier. "The pandemic has fortified our commitment to being ready to quickly support the innovative pharmaceutical partners we work with, whose drugs play an instrumental role in saving the lives of many."

"Continuous improvements and growth are at the core of our values at Jubilant. That is why we are very pleased to make this investment of US\$92Mn approx. in a state-of-the-art filling machine that features the highest degree of quality and compliance to meet current regulatory standards and service our customer's need even better" stated Pramod Yadav, CEO Jubilant Pharma Limited.

The new filling line will be commercially available by the end of 2024. Jubilant HollisterStier has already begun filling the 250 new roles created to support this expansion and is actively recruiting at this time.

### **About Jubilant HollisterStier LLC**

Jubilant HollisterStier LLC, a part of Jubilant Pharma Limited, is a leading integrated contract manufacturer of sterile injectables, ophthalmics, optics, sterile and non-sterile topicals and liquids. With facilities in North America, Jubilant HollisterStier provides specialized manufacturing for the pharmaceutical and biopharmaceutical industries. Services include a full-range of support to streamline the manufacturing process, from process qualifications through commercial release.

### **About Jubilant Pharma Limited**

Jubilant Pharma Limited (JPL), a company incorporated under the laws of Singapore and a wholly owned subsidiary of Jubilant Pharmova Limited, is an integrated global pharmaceutical company engaged in manufacturing and supply of Radiopharmaceuticals with a network of 48 radio-pharmacies in the US, Allergy Immunotherapy, Contract Manufacturing of Sterile Injectables and Non-sterile products, APIs and Solid Dosage Formulations through six manufacturing facilities that cater to all the regulated market including USA, Europe and other geographies. The Company has a team of around 5,200 multicultural people across the globe and is committed to deliver value to its customers spread across over 75 countries. It is well recognized as a 'Partner of Choice' by leading pharmaceutical companies globally.

### **About Jubilant Pharmova Limited**

Jubilant Pharmova Limited (formerly Jubilant Life Sciences Limited) is a company engaged in Pharmaceuticals, Contract Research and Development Services and Proprietary Novel Drugs businesses. Pharmaceuticals business through Jubilant Pharma Limited Singapore (JPL) is engaged in manufacturing and supply of Radiopharmaceuticals with a network of 48 radio-pharmacies in the US, Allergy Immunotherapy, Contract Manufacturing of Sterile Injectables and Non-sterile products, APIs and Solid Dosage Formulations through six manufacturing facilities that cater to all the regulated market including USA, Europe and other geographies. Jubilant Biosys Limited provides contract research and development services through two world class research centers in Bangalore and Noida in India. Jubilant Therapeutics is involved in Proprietary Novel Drugs business and is an innovative biopharmaceutical company developing breakthrough therapies in the area of oncology and auto-immune disorders. Jubilant Pharmova Limited has a team of over 6,000 multicultural people across the



globe. The Company is well recognized as a 'Partner of Choice' by leading pharmaceuticals companies globally. For more information, please visit: [www.jubilantpharmova.com](http://www.jubilantpharmova.com)

### ***Disclaimer***

Statements in this document relating to future status, events, or circumstances, including but not limited to statements about plans and objectives, the progress and results of research and development, potential product characteristics and uses, product sales potential and target dates for product launch are forward-looking statements based on estimates and the anticipated effects of future events on current and developing circumstances. Such statements are subject to numerous risks and uncertainties and are not necessarily predictive of future results. Actual results may differ materially from those anticipated in the forward-looking statements. Jubilant Pharmova may, from time to time, make additional written and oral forward looking statements, including statements contained in the company's filings with the regulatory bodies and its reports to shareholders. The company assumes no obligation to update forward-looking statements to reflect actual results, changed assumptions or other factors.